PMID- 36550924
OWN - NLM
STAT- MEDLINE
DCOM- 20221230
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 50
DP  - 2022 Dec 16
TI  - Invigorating spleen, replenishing qi and tonifying kidney method treatment of 
      traditional Chinese medicine for myasthenia gravis: A protocol for systematic 
      review and meta-analysis.
PG  - e32285
LID - 10.1097/MD.0000000000032285 [doi]
LID - e32285
AB  - BACKGROUND: Myasthenia gravis (MG) is an autoimmune disease related to the 
      production of autoantibodies. It is mediated by antibodies against acetylcholine 
      receptor (AChR), muscle specific kinase (MuSK) or other AChR related proteins in 
      the postsynaptic muscle membrane, which interfere with the transmission of 
      signals at the neuromuscular junction, resulting in clinical symptoms of skeletal 
      muscle weakness and fatigue, leading to the occurrence and development of MG. At 
      present, the incidence rate of Mg is increasing year by year. At present, the 
      method of invigorating spleen, replenishing qi and tonifying kidney in 
      traditional Chinese medicine has been widely used in the clinical treatment of 
      MG, and the effect is good. The purpose of this study was to systematically 
      evaluate the efficacy and safety of the method of invigorating the spleen, 
      supplementing qi and tonifying the kidney in the treatment of MG. METHODS: We 
      will search from the following eight databases: PubMed, Cochrane Library, EMBASE, 
      Web of Science, CNKI, Sinomed, Wanfang, and Vip. All randomized controlled trial 
      (RCT) literature has been searched and classified since the establishment of the 
      database to date. In this study, two researchers independently screened and 
      evaluated the quality of the retrieved literature. Cochrane risk bias assessment 
      tool was used to evaluate the risk of bias. The meta-analysis uses RevMan 5.3 
      software provided by Cochrane Collaboration Network for meta analysis. RESULTS: 
      This study compared the main outcome indicators: clinical response rate, 
      recurrence rate, incidence of adverse reactions, quantitative myasthenia gravis 
      score (QMG). Secondary outcomes were clinical absolute score, quality of life 
      score (QOL), levels of inflammatory factors such as IL-6, IL-10, and serum 
      acetylcholine receptor antibody (AChR-Ab) levels. CONCLUSION: The purpose of this 
      study was to evaluate the efficacy and safety of the method of invigorating the 
      spleen, supplementing qi and tonifying the kidney in treating MG, and to provide 
      evidence based medicine.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Liu, Miao
AU  - Liu M
AD  - Changchun University of Chinese Medicine, Jilin Province, China.
FAU - Wang, Hongan
AU  - Wang H
AD  - Affiliated Hospital of Changchun University of Chinese Medicine, Jilin Province, 
      China.
FAU - Lv, Zhiguo
AU  - Lv Z
AD  - Affiliated Hospital of Changchun University of Chinese Medicine, Jilin Province, 
      China.
FAU - Lu, Jing
AU  - Lu J
AD  - Affiliated Hospital of Changchun University of Chinese Medicine, Jilin Province, 
      China.
FAU - Zhang, Dongmei
AU  - Zhang D
AD  - Affiliated Hospital of Changchun University of Chinese Medicine, Jilin Province, 
      China.
FAU - Zhu, Zhiyue
AU  - Zhu Z
AD  - Changchun University of Chinese Medicine, Jilin Province, China.
FAU - Wu, Chunwei
AU  - Wu C
AD  - Changchun University of Chinese Medicine, Jilin Province, China.
FAU - Tian, Ye
AU  - Tian Y
AD  - Changchun University of Chinese Medicine, Jilin Province, China.
FAU - Song, Chaoqun
AU  - Song C
AD  - Changchun University of Chinese Medicine, Jilin Province, China.
FAU - Wu, Tong
AU  - Wu T
AD  - Changchun University of Chinese Medicine, Jilin Province, China.
FAU - Liu, Li
AU  - Liu L
AD  - Changchun University of Chinese Medicine, Jilin Province, China.
FAU - Chen, Xinzhi
AU  - Chen X
AUID- ORCID: 0000-0001-5166-1878
AD  - The First Clinical Hospital Research Institute of Jilin Academy of Chinese 
      Medicine, Jilin Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Receptors, Cholinergic)
SB  - IM
MH  - Humans
MH  - Kidney
MH  - Medicine, Chinese Traditional/methods
MH  - Meta-Analysis as Topic
MH  - *Myasthenia Gravis/drug therapy
MH  - Qi
MH  - Receptors, Cholinergic
MH  - *Spleen
MH  - Systematic Reviews as Topic
PMC - PMC9771329
COIS- The authors have no conflict of interest to disclose.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/27 06:00
PMCR- 2022/12/16
CRDT- 2022/12/23 01:07
PHST- 2022/12/23 01:07 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/27 06:00 [medline]
PHST- 2022/12/16 00:00 [pmc-release]
AID - 00005792-202212160-00132 [pii]
AID - 10.1097/MD.0000000000032285 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Dec 16;101(50):e32285. doi: 
      10.1097/MD.0000000000032285.